Todd Brady | Chief Executive Officer |
Joshua Reed | Chief Financial Officer |
Yigal Nochomovitz | Citi Investment Research |
Sudan Loganathan | Cantor Fitzgerald & Company |
Esther Hong | Janney Montgomery Scott |
Adam Walsh | Stifel, Nicolaus & Company |
Matthew Cross | JonesTrading Institutional Services |
Good morning and to welcome to the Aldeyra Therapeutics Third Quarter 2019 Financial Results Call. My name is Andria, and I will be your operator today. [Operator Instructions]
At this time, I would like to turn the call over to Mr. Joshua Reed, the Company's Chief Financial Officer.